樂普醫療(300003.SZ)擬向參股公司樂普生物增資及放棄股權轉讓優先受讓權
格隆匯4月10日丨樂普醫療(300003.SZ)公佈,公司於2018年1月與公司實際控制人蒲忠傑先生控股的寧波厚德義民信息科技有限公司(厚德科技)共同設立樂普生物科技有限公司(樂普生物),公司持有樂普生物20%股權。
此次公司擬與深圳市拾玉投資管理有限公司、蘇州民營資本投資控股有限公司等共8家投資機構共同向樂普生物增資4.5億元,其中公司出資9000萬元。增資後,樂普生物註冊資本將由10億元增至約11.27億元,公司仍將持有樂普生物20%股權;厚德科技擬將其持有的樂普生物11.25%股權轉讓給上述8家投資機構,公司擬放棄該部分股權轉讓的優先受讓權。
樂普生物科技有限公司主營業務:樂普生物圍繞腫瘤免疫治療和靶向藥物,開發研製PD-1/L1單克隆抗體(單抗)和ADC靶向藥物以及核心聯合用藥(溶瘤病毒、ADC)的創新型腫瘤治療產品平台;搭建靶點發現、成藥研製、開發和生產的開放性產業平台。
參與設立樂普生物,是公司經過審慎評估,前瞻性戰略佈局腫瘤免疫治療領域而作出的決策。小股權參股,既降低了公司初期進入該領域的可能風險,同時也可享受樂普生物成功帶來的巨大收益,為公司未來進入該領域開闢路徑。
目前樂普生物產品研發、臨牀進展順利,已建立起單雙抗體、溶瘤病毒、抗體偶聯藥等多個生物藥開發技術平台,多個產品在臨牀管線中穩步推進;同時產業平台建設有序進行,北京生產基地已經投入使用,上海生產基地正在建設中。此次增資樂普生物,符合公司長期發展戰略,有利於提升公司未來在腫瘤免疫治療領域的核心競爭力,增強公司長期發展新動能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.